Replies to post #4203 on RespireRx Pharmaceuticals Inc (fka RSPI)

[moosedogger]

R&R's price target of $4.50 is a joke -- they're the same guys who had a $12 price target not too long ago.

R&R are good guys as far as I know.

$12 wasn't out of line- it could have gotten there if the hold hadn't happened a year ago.

Neuro had the same $12 target- and he's certainly as credible as they come, actually even more so.

$4.50 may seem high but are they talking post-FDA approval or before? I don't know.

BTW- weren't you extolling the possibility of $50 not that long ago? I think I recall you even mentioned that number to Stoll and he said something like (I'm paraphrasing) "I hope you're right but don't get your hopes up"

I think today is all about China

3-4 PM could be interesting.

cheers

[jerrydylan]

I watched for 2 years, the end of cx-516 the beginning of 717 and it's phase 1 before getting in 2 years ago, bought Neuro's work so I knew more about the science, the application and AMPA. I think the science is worth alot more than the stock and the science's time has come-could it be cx717, yes...Organon? A Lilly partnership? AMPA is going to be a big deal IMHO. Let me tell you how it works with the stock: this thing will move when the institutions want it to, they won't tell you or me-so I watch their tracks in the snow. They have the ability to get Stoll's ear and this appeared to me all last 2 weeks when the money flow was strong and the stock kept absorbing supply--little news from the company ...boom. When you see that much volume off a decent bottom, it is likely not over this early and unlike the markets in general it is very oversold still on a monthly chart with most weak hands wrenched out.